Mirae Asset Global Investments Co. Ltd. Buys New Position in Novo Nordisk A/S $NVO

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 263,943 shares of the company’s stock, valued at approximately $10,006,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Novo Nordisk A/S during the first quarter worth $287,660,000. State Street Corp boosted its holdings in Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after purchasing an additional 32,641 shares during the period. Envestnet Asset Management Inc. grew its stake in Novo Nordisk A/S by 1.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after purchasing an additional 71,684 shares in the last quarter. Royal Bank of Canada grew its stake in Novo Nordisk A/S by 3.2% during the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after purchasing an additional 141,376 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after purchasing an additional 213,443 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 5.0%

Shares of NYSE NVO opened at $42.21 on Thursday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a market capitalization of $188.45 billion, a price-to-earnings ratio of 10.32, a price-to-earnings-growth ratio of 1.36 and a beta of 0.70. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The business has a 50-day moving average of $40.84 and a two-hundred day moving average of $44.07.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The business had revenue of $11.98 billion for the quarter. On average, analysts forecast that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ estimates for third-quarter earnings and revenue. Adjusted sales rose 4%, adjusted operating profit increased 27%, and obesity-drug sales climbed 22%. The company raised its full-year 2026 sales and operating-profit outlook. Reuters report on earnings and guidance
• Positive Sentiment: Wegovy pill sales exceeded Wall Street expectations, giving Novo a promising early foothold in the oral weight-loss drug market and helping drive the outlook upgrade. CEO Mike Doustdar said the launch had exceeded expectations. BioPharma Dive report on Wegovy pill sales
• Neutral Sentiment: Doustdar declined to provide 2027 guidance, leaving investors without a clear view of growth beyond this year. Novo’s CFO Karsten Munk Knudsen is also expected to leave the company. Article on earnings, outlook and 2027 guidance
• Negative Sentiment: Pricing pressure and weaker diabetes performance remain risks to growth, while impairment charges weighed on reported operating profit. Competition from Eli Lilly also remains a concern, especially as the oral obesity-drug market develops. Zacks analysis of earnings and risks

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. UBS Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Berenberg Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $59.44.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.